RxDoctor Payments Data

Meegan Mangum, PA

Physician Assistant · Portland, ORNPI 1760818447

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (49.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Abbott accounts for 94.5% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $13,937, more than ten times the $264 reported in 2021. Among physician assistant clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$24,765in general payments, 2019–2025

Across 114 payments — averaging $217.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$23K
  • Ancora Heart, Inc.$528
  • Cvrx, Inc.$216
  • AstraZeneca$202
  • Abiomed$131
  • Boston Scientific$82
  • plus $202 from 4 others

What the payments were for

  • Consulting fees$12,34250%
  • Travel & lodging$9,24737%
  • Food & beverage$3,10113%
  • Education$750%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,765 in reported general payments places this provider in the 95th percentile of 1,756 physician assistant providers in Oregon.

See all physician assistant providers in Oregon

Medicare billing

Part B allowed, 2024
$32,478
Medicare patients
173
Services billed
372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan191$239,155
EliquisApixaban86$90,606
JardianceEmpagliflozin62$84,093
FarxigaDapagliflozin Propanediol95$77,330
XareltoRivaroxaban24$22,516
Repatha SyringeEvolocumab11$6,003
Metoprolol Succinate187$2,829
Eplerenone30$2,560
Torsemide101$2,403
Potassium Chloride62$1,757
Bumetanide50$1,642
Spironolactone159$1,309
Atorvastatin Calcium50$873
Carvedilol72$699
Losartan Potassium59$668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$46$239,155191 claims
AstraZenecaFarxiga$202$77,33095 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,756 physician assistant providers in Oregon.

Other physician assistant in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →